Literature DB >> 22549283

Novel data-mining methodologies for adverse drug event discovery and analysis.

R Harpaz1, W DuMouchel, N H Shah, D Madigan, P Ryan, C Friedman.   

Abstract

An important goal of the health system is to identify new adverse drug events (ADEs) in the postapproval period. Datamining methods that can transform data into meaningful knowledge to inform patient safety have proven essential for this purpose. New opportunities have emerged to harness data sources that have not been used within the traditional framework. This article provides an overview of recent methodological innovations and data sources used to support ADE discovery and analysis.

Entities:  

Mesh:

Year:  2012        PMID: 22549283      PMCID: PMC3675775          DOI: 10.1038/clpt.2012.50

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  56 in total

1.  Accelerated clinical discovery using self-reported patient data collected online and a patient-matching algorithm.

Authors:  Paul Wicks; Timothy E Vaughan; Michael P Massagli; James Heywood
Journal:  Nat Biotechnol       Date:  2011-04-24       Impact factor: 54.908

2.  Predicting adverse drug events using pharmacological network models.

Authors:  Aurel Cami; Alana Arnold; Shannon Manzi; Ben Reis
Journal:  Sci Transl Med       Date:  2011-12-21       Impact factor: 17.956

3.  Estimating treatment effects using observational data.

Authors:  Ralph B D'Agostino; Ralph B D'Agostino
Journal:  JAMA       Date:  2007-01-17       Impact factor: 56.272

4.  Drug safety reform at the FDA--pendulum swing or systematic improvement?

Authors:  Mark McClellan
Journal:  N Engl J Med       Date:  2007-04-13       Impact factor: 91.245

5.  Managing drug-risk information--what to do with all those new numbers.

Authors:  Jerry Avorn; Sebastian Schneeweiss
Journal:  N Engl J Med       Date:  2009-07-27       Impact factor: 91.245

6.  A Bayesian neural network method for adverse drug reaction signal generation.

Authors:  A Bate; M Lindquist; I R Edwards; S Olsson; R Orre; A Lansner; R M De Freitas
Journal:  Eur J Clin Pharmacol       Date:  1998-06       Impact factor: 2.953

7.  Using information mining of the medical literature to improve drug safety.

Authors:  Kanaka D Shetty; Siddhartha R Dalal
Journal:  J Am Med Inform Assoc       Date:  2011-05-05       Impact factor: 4.497

Review 8.  Contrast media and nephropathy: findings from systematic analysis and Food and Drug Administration reports of adverse effects.

Authors:  Richard Solomon; William Dumouchel
Journal:  Invest Radiol       Date:  2006-08       Impact factor: 6.016

9.  Mining multi-item drug adverse effect associations in spontaneous reporting systems.

Authors:  Rave Harpaz; Herbert S Chase; Carol Friedman
Journal:  BMC Bioinformatics       Date:  2010-10-28       Impact factor: 3.169

10.  The tell-tale heart: population-based surveillance reveals an association of rofecoxib and celecoxib with myocardial infarction.

Authors:  John S Brownstein; Margarita Sordo; Isaac S Kohane; Kenneth D Mandl
Journal:  PLoS One       Date:  2007-09-05       Impact factor: 3.240

View more
  130 in total

1.  A Multiagent System for Integrated Detection of Pharmacovigilance Signals.

Authors:  Vassilis Koutkias; Marie-Christine Jaulent
Journal:  J Med Syst       Date:  2015-11-21       Impact factor: 4.460

2.  Text mining for adverse drug events: the promise, challenges, and state of the art.

Authors:  Rave Harpaz; Alison Callahan; Suzanne Tamang; Yen Low; David Odgers; Sam Finlayson; Kenneth Jung; Paea LePendu; Nigam H Shah
Journal:  Drug Saf       Date:  2014-10       Impact factor: 5.606

Review 3.  Utilizing social media data for pharmacovigilance: A review.

Authors:  Abeed Sarker; Rachel Ginn; Azadeh Nikfarjam; Karen O'Connor; Karen Smith; Swetha Jayaraman; Tejaswi Upadhaya; Graciela Gonzalez
Journal:  J Biomed Inform       Date:  2015-02-23       Impact factor: 6.317

4.  Analyzing the Usage of Standards in Radiation Therapy Clinical Studies.

Authors:  Y Zhen; Y Jiang; L Yuan; J Kirkpartrick; J Wu; Y Ge
Journal:  IEEE EMBS Int Conf Biomed Health Inform       Date:  2017-04-13

5.  Automatic signal extraction, prioritizing and filtering approaches in detecting post-marketing cardiovascular events associated with targeted cancer drugs from the FDA Adverse Event Reporting System (FAERS).

Authors:  Rong Xu; Quanqiu Wang
Journal:  J Biomed Inform       Date:  2013-10-28       Impact factor: 6.317

Review 6.  Legal and regulatory considerations associated with use of patient-generated health data from social media and mobile health (mHealth) devices.

Authors:  C Petersen; P DeMuro
Journal:  Appl Clin Inform       Date:  2015-01-14       Impact factor: 2.342

7.  Pharmacovigilance via Baseline Regularization with Large-Scale Longitudinal Observational Data.

Authors:  Zhaobin Kuang; Peggy Peissig; Vítor Santos Costa; Richard Maclin; David Page
Journal:  KDD       Date:  2017-08

8.  Signalling paediatric side effects using an ensemble of simple study designs.

Authors:  Jenna M Reps; Jonathan M Garibaldi; Uwe Aickelin; Daniele Soria; Jack E Gibson; Richard B Hubbard
Journal:  Drug Saf       Date:  2014-03       Impact factor: 5.606

9.  tcTKB: an integrated cardiovascular toxicity knowledge base for targeted cancer drugs.

Authors:  Rong Xu; QuanQiu Wang
Journal:  AMIA Annu Symp Proc       Date:  2015-11-05

Review 10.  Integrative approaches for predicting in vivo effects of chemicals from their structural descriptors and the results of short-term biological assays.

Authors:  Yen Sia Low; Alexander Yeugenyevich Sedykh; Ivan Rusyn; Alexander Tropsha
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.